Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Sustained Virological Suppression and Improvement of Adverse Events of Switching to Raltegravir Study (TaISENWITCH)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Lin, Hsi-Hsun, M.D.
ClinicalTrials.gov Identifier:
NCT01679964
First received: August 30, 2012
Last updated: September 14, 2016
Last verified: September 2016
  Purpose
Switching from the ritonavir-boosted protease inhibitor component to raltegravir in stable HIV-infected adult patients receiving combination therapy will demonstrate improved clinical tolerability or lipid profiles with sustained plasma virological response (<50 copies/ml).

Condition Intervention Phase
HIV Infection
Adverse Drug Reaction
Quality of Life
Drug: Raltegravir switch
Phase 4

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Single Arm Study to Assess the Sustained Virological Suppression and Improvement of Treatment-emerged Adverse Events of Switching to Raltegravir in Stable HIV-infected Patients on Ritonavir-boosted Protease Inhibitor Regimen

Resource links provided by NLM:


Further study details as provided by Lin, Hsi-Hsun, M.D.:

Primary Outcome Measures:
  • The proportion of patient-reported clinical adverse events [ Time Frame: Week 4, 12-16, 28-32, 48 ] [ Designated as safety issue: Yes ]
    The proportion of patient-reported clinical adverse events in total and by severity (based on symptom distress module) at 4 weeks, The proportion of patient-reported clinical adverse events in total and by severity (based on symptom distress module) at 12-16 weeks, The proportion of patient-reported clinical adverse events in total and by severity (based on symptom distress module) at 28-32 weeks, The proportion of patient-reported clinical adverse events in total and by severity (based on symptom distress module) at 48 weeks


Secondary Outcome Measures:
  • The proportion of patients who are free of "virological failure" [ Time Frame: Week 4, 12-16, 28-32, 48 ] [ Designated as safety issue: No ]
    The proportion of patients who are free of "virological failure" at week 4 after switch, The proportion of patients who are free of "virological failure" at week 12-16 after switch, The proportion of patients who are free of "virological failure" at week 28-32 after switch, The proportion of patients who are free of "virological failure" at week 48 after switch

  • The change from baseline in CD4 cell counts [ Time Frame: Week 4, 12-16, 28-32, 48 ] [ Designated as safety issue: No ]
    The change from baseline in CD4 cell counts at week 4 after switch, The change from baseline in CD4 cell counts at week 12-16 after switch, The change from baseline in CD4 cell counts at week 28-32 after switch, The change from baseline in CD4 cell counts at week 48 after switch

  • the change from baseline in life quality (based on the MOS-HIV questionnaire) [ Time Frame: week 12-16, 48 ] [ Designated as safety issue: No ]
    The change from baseline in quality of life (based on the MOS-HIV questionnaire) at week 12-16 after switch, The change from baseline in quality of life (based on the MOS-HIV questionnaire) at week 48 after switch.

  • The percent changes from baseline in plasma lipid profiles (total cholesterol, LDL Cholesterol, HDL Cholesterol, triglycerides) [ Time Frame: Week 4, 12-16, 28-32, 48 ] [ Designated as safety issue: No ]
    The percent changes from baseline in plasma lipid profiles (total cholesterol, LDL Cholesterol, HDL Cholesterol, triglycerides) at 4 weeks, The percent changes from baseline in plasma lipid profiles (total cholesterol, LDL Cholesterol, HDL Cholesterol, triglycerides) at 12-16 weeks, The percent changes from baseline in plasma lipid profiles (total cholesterol, LDL Cholesterol, HDL Cholesterol, triglycerides) at 28-32 weeks, The percent changes from baseline in plasma lipid profiles (total cholesterol, LDL Cholesterol, HDL Cholesterol, triglycerides) at 48 weeks

  • The proportion of patients with treatment failure [ Time Frame: Week 4, 12-16, 28-32, 48 ] [ Designated as safety issue: No ]
    The percent changes from baseline in plasma lipid profiles (total cholesterol, LDL Cholesterol, HDL Cholesterol, triglycerides) at 4 weeks, The percent changes from baseline in plasma lipid profiles (total cholesterol, LDL Cholesterol, HDL Cholesterol, triglycerides) at 12-16 weeks, The percent changes from baseline in plasma lipid profiles (total cholesterol, LDL Cholesterol, HDL Cholesterol, triglycerides) at 28-32 weeks, The percent changes from baseline in plasma lipid profiles (total cholesterol, LDL Cholesterol, HDL Cholesterol, triglycerides) at 48 weeks


Enrollment: 107
Study Start Date: July 2012
Study Completion Date: February 2015
Primary Completion Date: February 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Raltegravir switch
Isentress (400mg) bid + 2 NRTI (at least 2 nucleoside or nucleotide reverse transcriptase inhibitors and no other protease inhibitors)
Drug: Raltegravir switch
Isentress (400mg) bid + 2 NRTI (at least 2 nucleoside or nucleotide reverse transcriptase inhibitors and no other protease inhibitors)
Other Name: Isentress

Detailed Description:

A. Objectives To compare the treatment-emerged AEs and virological suppression after switch to raltegravir-based therapy in stable HIV-infected patients who receiving ritonavir-boosted protease inhibitor antiretroviral regimen

Primary endpoints:

1) The changes in overall incidence and severity of patient-reported clinical adverse events (based on "symptom distress module) after switch to raltegravir-based therapy.

Secondary endpoints:

  1. The proportion of patients who are free of "virological failure" at week 48 after switch
  2. The change from baseline in CD4 cell counts at week 48 after switch
  3. The change in quality of life by assess the changes in the domain scores of MOS-HIV questionnaire at baseline and different study time points.
  4. The changes in laboratory adverse event, e.g., the mean percent changes from baseline to 48 weeks in plasma lipid profile (total cholesterol, LDLCholesterol, HDL Cholesterol, triglycerides) after switch
  5. The proportion of patients who are free of "treatment failure" at week 48 after switch

Safety endpoints

  1. Incidence of adverse events
  2. The proportion of patients with treatment-related grade 3 or 4 adverse events and laboratory abnormalities
  Eligibility

Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients who are infected with HIV-1
  • Ages at least 20 years
  • Patients are currently receiving a ritonavir-boosted PI-based regimen, including lopinavir, atazanavir, or darunavir, plus at least 2 antiretroviral agents (NRTIs)
  • Patient complained of treatment-emerged clinical adverse events or abnormal lipid profile
  • Patients with plasma HIV-1 viral RNA below 50 copies per ml for at least 6 months

Exclusion Criteria:

  • Patient with known history of contraindication or hypersensitivity to any component of the study regimen
  • Patients with acute or decompensated chronic hepatitis in the previous 6 months
  • Patients with chronic hepatitis and serum aminotransferase concentrations are more than 5 times the upper limit of the normal range
  • Patients with renal insufficiency (patients need dialysis or have serum creatinine concentrations of more than twice the upper limit of the normal range
  • Current alcohol or substance abuse (patients receiving methadone for the management of withdrawal symptoms due to substance abuse are allowed )
  • Patients have failed previous regimens (prior to starting the current 2NRTI+PI/r regimen they are currently on)
  • Patient's viral load have not been consistently <50 copies per ml for 6 months or longer.
  • Patients initiated lipid lowering agents during the preceding 3 months
  • Patients with any medical disorder or history of any illness which, in the opinion of the investigator, that the use of study medications is contraindicated or might confound the results of the study or pose additional risk in administering study drugs to the patient
  • Pregnant, wish to become pregnant during the study period or breastfeeding women
  • Patients who are lack of expectation to maintain assigned study medication during study period
  • Patients who have received therapy with investigational drugs in the previous 3 months
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01679964

Locations
Taiwan
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung, Taiwan, 807
E-Da Hospital
Kaohsiung, Taiwan, 824
China Medical University Hospital
Taichung, Taiwan, 40447
National Cheng Kung University Hospital
Tainan, Taiwan, 704
National Taiwan University Hospital
Taipei, Taiwan, 10048
Taipei City Hospital
Taipei, Taiwan, 108
Chang Gung Memorial Hospital at Linkou
Taoyuan, Taiwan, 333
Sponsors and Collaborators
Lin, Hsi-Hsun, M.D.
Investigators
Principal Investigator: Hsi-Hsun Lin, MD E-DA Hospital
  More Information

Publications:
Walensky RP. The survival benefits of AIDS treatment in the US. J Infect Dis 2006;194:11-19 Lennox JL. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection. Lancet 2009;374:796-806 Steigbigel RT. Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection. Clin Infect Dis 2010;50:605-12 Eron JJ. Switch to raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2). Lancet 2010;375:396-407 Martinex E. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. AIDS 2010, 24:1697-1707 Division of AIDS(DAIDS). Toxicity guideline for adults. http://rcc.tech-res.com/safetyand pharmacovigilance(accessed Apr 15, 2011)

Responsible Party: Lin, Hsi-Hsun, M.D.
ClinicalTrials.gov Identifier: NCT01679964     History of Changes
Other Study ID Numbers: MISP40301  MISP 40301 
Study First Received: August 30, 2012
Last Updated: September 14, 2016
Health Authority: Taiwan: Department of Health
Individual Participant Data  
Plan to Share IPD: No

Keywords provided by Lin, Hsi-Hsun, M.D.:
HIV infection
Raltegravir
Adverse event
Life quality

Additional relevant MeSH terms:
HIV Infections
Drug-Related Side Effects and Adverse Reactions
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Chemically-Induced Disorders
Raltegravir Potassium
Protease Inhibitors
HIV Protease Inhibitors
Reverse Transcriptase Inhibitors
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
HIV Integrase Inhibitors
Integrase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors

ClinicalTrials.gov processed this record on September 29, 2016